Bristol-Myers Squibb announces global collaboration with leading academic institutions

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the intelligence of the body's own immune system to fight cancer. In addition to Bristol-Myers Squibb, the II-ON is currently comprised of ten leading cancer-research institutions, including:
  • Clinica Universidad Navarra, Pamplona, Spain
  • Dana-Farber Cancer Institute, Boston, MA
  • The Earle A. Chiles Research Institute (Providence Health & Services), Portland, OR
  • Institut Gustave Roussy, Villejuif, France
  • Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale,” Naples, Italy
  • Johns Hopkins Kimmel Cancer Center, Baltimore MD
  • Memorial Sloan-Kettering Cancer Center, New York, NY
  • The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
  • The Netherlands Cancer Institute, Amsterdam, NL
  • The University of Chicago, Chicago, IL

An objective of this collaborative forum is to facilitate the translation of scientific research findings into clinical trials and, eventually, clinical practice. It will also work to further advance innovation in drug discovery and development.

"The International Immuno-Oncology Network facilitates a public-private partnership that will leverage intellectual capabilities across a global network," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "The shared commitment of all those participating in this collaboration is to evolve our understanding of immuno-oncology towards our ultimate goal of improving patient outcomes."

The role of immuno-oncology in cancer research is growing and in 2011 the concept of "evading immune destruction" was added to the "Hallmarks of Cancer," a widely-referenced peer-reviewed article outlining traits that are believed to be the underlying principles of cancer.

Immuno-Oncology at Bristol-Myers Squibb
The substantial potential of the immune system's intrinsic ability to fight cancer is fundamental to immuno-oncology research at Bristol-Myers Squibb and its ongoing commitment to advancing cancer care. The company is exploring a variety of compounds and immunotherapeutic approaches for patients with different types of cancer, and the formation of the II-ON is an important example of the company's commitment to this area of research.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

SMi Group announces the 9th Annual RNA Therapeutic…

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]